Common Contracts

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. LICENSE AGREEMENT

License Agreement • November 4th, 2011 • Novavax Inc • Biological products, (no disgnostic substances) • New York

• Contract Type
  License Agreement
• Filed
  November 4th, 2011
• Company
  Novavax Inc
• Industry
  Biological products, (no disgnostic substances)
• Jurisdiction
  New York

If a Product is sold as part of a combination product, the Net Sales from the combination product shall be determined by multiplying the Net Sales (as determined above) of the combination product by [***] In case the average sales price of the Product when sold alone or any of the other product(s) cannot be determined, then the Parties shall negotiate in good faith and agree upon in writing an appropriate methodology for determining the basis of calculating the Net Sales of the combination product based on the fair market value thereof and other reasonable assessments.

LICENSE AGREEMENT

License Agreement • May 10th, 2011 • Novavax Inc • Biological products, (no disgnostic substances) • New York

• Contract Type
  License Agreement
• Filed
  May 10th, 2011
• Company
  Novavax Inc
• Industry
  Biological products, (no disgnostic substances)
• Jurisdiction
  New York

This License Agreement (the “Agreement”) is entered into as of December 9th, 2010 (“Signing Date”) by and between Novavax Inc., having its principal place of business at 9920 Belward Campus Drive, Rockville, MD 20850, USA (“NOVAVAX”) and LG Life Sciences, Ltd., having its principal place of business at LG Gwanghwamun Bldg., 92 Sinmunno 2-ga, Jongno-gu, Seoul, Republic of Korea (“LGLS”). NOVAVAX and LGLS may each be referred to as a “Party” and collectively as the “Parties.”